These results correlate with the studies by Arnold and colleagues, which demonstrated that the combination treatment of devimistat—a drug that acts as an inhibitor of the mitochondrial enzymes pyruvate dehydrogenase (PHD) and α-ketoglutarate dehydrogenase (KGDH), interfering with the altered energy metabolism of tumor cells— with 5FU or irinotecan caused a synergistic effect HCT116 colorectal cancer cell line [32]. This evidence concerns the gene PDC and neoplasm.